<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04393753</url>
  </required_header>
  <id_info>
    <org_study_id>4SC-202-3-2018</org_study_id>
    <secondary_id>2018-004788-30</secondary_id>
    <nct_id>NCT04393753</nct_id>
  </id_info>
  <brief_title>Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1</brief_title>
  <acronym>MERKLIN2</acronym>
  <official_title>A Phase II, Open Label Study to Investigate the Efficacy and Safety of Domatinostat in Combination With Avelumab in Patients With Advanced Unresectable/Metastatic Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 Antibody Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>4SC AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>4SC AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well domatinostat (4SC-202) works in combination with
      avelumab in adult patients with advanced unresectable and/or metastatic Merkel Cell Carcinoma
      that have progressed on a previous therapy with an anti-PD-(L)1 antibody
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Objective Response Rate (ORR) defined as the percentage of patients having a confirmed CR or PR according to RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durable Response Rate (DRR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Durable Response Rate (DRR), defined as the percentage of patients having a RECIST v1.1 response lasting ≥ 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Duration of Response (DoR), defined as the time from an initial objective response (CR or PR) according to RECIST v1.1 until disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Disease Control Rate (DCR), defined as the proportion of patients with either an objective response (CR, PR) or stable disease (SD) according to RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durable Disease Control Rate (dDCR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Durable Disease Control Rate (dDCR), defined as the percentage of patients having a RECIST v1.1 disease control lasting ≥ 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall response (BOR)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Best Overall response (BOR), defined as the best response (PD, SD, PR, CR) according to RECIST v1.1 over the course of a patient's participation in the study, assessed up to 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Progression Free Survival (PFS), defined as the time from first dosing (Day +1) to the date of PD or death from any cause (whichever comes first)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS Rate</measure>
    <time_frame>up to 24 months</time_frame>
    <description>PFS Rate, defined as the percentage of patients without PD at 6 and 12 months after first administration of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Overall Survival (OS), defined as the time from the first administration of study medication until death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS Rate</measure>
    <time_frame>up to 12 months</time_frame>
    <description>OS Rate, defined as the percentage of patients alive at 6 and at 12 months after first administration of study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Safety and Tolerability of the study medication (determined by number, frequency, duration and severity of AEs using CTCAE v5.0, physical examination, laboratory tests, vital signs, and ECGs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of Life (HrQoL)</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The impact of treatment on the patient's QoLwill be assessed with the questionnaires &quot;Functional Assessment of Cancer Therapy - Melanoma (FACT-M)&quot; where QoL is assessed on a scale 0-240 (higher score means better status of health), with &quot;EQ-5D-5L&quot; which is a multi attribute utility instrument for measuring health-related QoL as EQ5D index with a score 0-1 (higher score means better status of health) and with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30) with a score 0-100 per subscale (n=9 per item (n=6), higher score means better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of domatinostat and avelumab</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Single trough values of domatinostat and avelumab at pre-defined time points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Avelumab anti-drug antibodies (ADA)</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Avelumab anti-drug antibodies (ADA)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Merkel Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>domatinostat and avelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm study of Domatinostat tablets in combination with avelumab infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>domatinostat in combination with avelumab</intervention_name>
    <description>domatinostat tablets and avelumab infusion</description>
    <arm_group_label>domatinostat and avelumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed Merkel Cell Carcinoma (MCC)

          -  ECOG performance status ≤ 1

          -  MCC in an advanced, unresectable stage III or metastatic stage IV (includes patients
             who refused surgical resection or are not eligible for such surgical resection)

          -  Progressing on previous anti-PD-(L)1 antibody monotherapy within the last 12 weeks
             before planned first administration of study medication

        Exclusion Criteria:

          -  History of serious anti-PD-(L)1 therapy-related adverse reactions prohibiting further
             avelumab treatment

          -  More than one line of previous systemic anti-neoplastic therapy other than
             anti-PD-(L)1 antibody monotherapy

          -  Palliative radiation therapy of single lesions within 2 weeks before planned
             administration of study medication

          -  Absence of significant active or chronic disease (infections, immunodeficiencies,
             cardiovascular, psychiatric disorders)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chief Medical Officer</last_name>
    <phone>+49 (0)89 700 7630</phone>
    <email>medical.request@4sc.com</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 12, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

